Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Nesiritide (Natrecor)32 residuesSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRHEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Natrecor, rhBNP, BNP-32
Seven thousand one hundred and forty-one patients enrolled in ASCEND-HF, and the result was a clear "cannot be recommended for routine use." Nesiritide (Natrecor) is a recombinant copy of human B-type natriuretic peptide, a 32-amino-acid hormone your ventricles release when they're overloaded. The FDA approved it in 2001 for acute decompensated heart failure, and it does lower pulmonary capillary wedge pressure fast. The problem: it never proved it saves lives. Clinical use dropped 64% after the 2005 mortality signal, and the drug has since been discontinued from the US market. It remains a textbook example of hemodynamic improvement without clinical benefit.
Nesiritide (brand name Natrecor, CAS 124584-08-9) is a recombinant form of the 32-amino-acid human B-type natriuretic peptide. The ASCEND-HF trial [1] concluded it "cannot be recommended for routine use in the broad population of patients with acute heart failure," and that verdict effectively ended its clinical life. Your ventricular cardiomyocytes produce this same molecule when wall stress climbs too high. The synthetic version binds natriuretic peptide receptor-A, triggers cGMP production, and relaxes both arteries and veins. Hemodynamic effects start within 15 minutes of an IV bolus. The early data looked good. The VMAC trial (2002)[2] showed nesiritide reduced pulmonary capillary wedge pressure better than IV nitroglycerin and improved dyspnea scores. Cardiologists prescribed it widely; peak-year revenue exceeded expectations. Then came the Sackner-Bernstein meta-analysis in 2005 [3], which flagged a 74% increased 30-day mortality signal (p=0.059). Prescriptions dropped 64% almost overnight. ASCEND-HF settled the question in 2011. Across 7,141 patients with acute decompensated heart failure, nesiritide modestly improved dyspnea at 6 and 24 hours but missed the pre-specified significance threshold. Thirty-day mortality was 3.6% versus 4.0% for placebo; rehospitalization showed no difference either. The drug has since been pulled from the US market. It is not available for new clinical use from any legitimate source.
Nesiritide is identical in sequence to the BNP your ventricular myocardium releases under volume overload. The target is natriuretic peptide receptor-A (NPR-A), also called guanylyl cyclase-A, found on vascular smooth muscle, endothelial cells, renal tubules, and adrenal tissue. Binding activates the receptor's intracellular guanylyl cyclase domain. GTP converts to cyclic GMP; cGMP activates protein kinase G. PKG then dephosphorylates myosin light chains and lowers intracellular calcium in smooth muscle. The result is vasodilation in both arterial and venous beds, reducing preload and afterload simultaneously. In the kidneys, cGMP signaling increases glomerular filtration and blocks sodium reabsorption in the collecting ducts. That produces natriuresis and diuresis. Nesiritide also suppresses the renin-angiotensin-aldosterone system and dials down sympathetic nervous system activity, adding to the hemodynamic relief. Three clearance pathways handle elimination: NPR-C clearance receptors internalize and degrade it lysosomally; neprilysin (neutral endopeptidase) cleaves it proteolytically; and the kidneys filter it directly. The plasma half-life is just 18 minutes, but here's the catch. Blood pressure effects last roughly 2.2 hours on average. That pharmacodynamic tail is what makes hypotension management so tricky; stopping the infusion doesn't fix the problem quickly.
Nesiritide reduces PCWP and improves dyspnea in ADHF (VMAC, 2002). ASCEND-HF (2011, n=7,141) showed no mortality or rehospitalization benefit vs placebo; guideline conclusion: "cannot be recommended for routine use." Drug subsequently withdrawn from the US market. 2005 Sackner-Bernstein meta-analysis flagged 74% increased 30-day mortality signal (p=0.059)[3], not confirmed in ASCEND-HF.
ASCEND-HF (O'Connor et al., NEJM 2011, PMID 21732835)
Modest dyspnea improvement at 6 and 24 hours missed pre-specified significance threshold. No survival benefit. PD half-life (~2.2 h for hypotension) substantially exceeds PK half-life (18 min), complicating hemodynamic management. Drug discontinued: no longer available for new use.
No community or self-administration use exists. Nesiritide is a hospital-only IV drug discontinued from the US market.
No community self-administration data exists. All evidence is from clinical trials and the FDA label. Drug is discontinued and was never available outside monitored hospital settings.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2 mcg/kg | IV bolus + 0.01 mcg/kg/min infusion |
| Moderate | 2 mcg/kg | IV bolus + 0.01 mcg/kg/min infusion |
| Aggressive | 2 mcg/kg | IV bolus + 0.03 mcg/kg/min infusion |
Nesiritide is discontinued from the US market. This page exists for clinical reference, not practical sourcing guidance. You won't find it through any legitimate supply channel. When it was available, each 1.5 mg vial got reconstituted with 5 mL of diluent pulled from a 250 mL IV bag (D5W, normal saline, or 5% dextrose/0.2% NaCl). That gave 0.32 mg/mL in the vial. The entire contents then went back into the 250 mL bag for a final concentration of roughly 6 mcg/mL. For a 70 kg patient: the bolus is 2 mcg/kg = 140 mcg, which is about 23 mL of the 6 mcg/mL solution, given over 60 seconds. Maintenance runs at 0.01 mcg/kg/min = 0.7 mcg/min = 7 mL/hr on the infusion pump. The thing most residents miss: stopping the infusion doesn't stop the hypotension. Plan for 2+ hours of blood pressure monitoring after you turn it off. And never run it through the same line as heparin or furosemide; it precipitates.
Nesiritide is used exclusively for acute treatment of decompensated heart failure in hospitalized settings, typically as a single continuous infusion lasting up to 48 hours. It is not cycled and is not intended for outpatient, intermittent, or scheduled repetitive use.
No cycling concept applies. Nesiritide is used for a single acute episode (one hospitalization). It is explicitly not for outpatient, intermittent, or scheduled repeated use. The drug has since been discontinued from the US market.
Or use the universal Peptide Calculator for any peptide.
Expected: Rapid PCWP reduction within 15 minutes. Modest dyspnea improvement at 6-24 hours. No demonstrated mortality or rehospitalization benefit (ASCEND-HF).
Monitor: Continuous BP monitoring required. Target systolic BP ≥90 mmHg. Serum creatinine and eGFR baseline and daily. PCWP monitoring if pulmonary artery catheter in place. Urine output to assess natriuresis.
Confirm the patient has acute decompensated heart failure with dyspnea at rest or with minimal activity. This drug is hospital-only, requiring continuous hemodynamic monitoring.
Pull 5 mL of diluent from a pre-filled 250 mL IV bag (D5W, 0.9% NaCl, or 5% dextrose/0.2% NaCl). Inject into the 1.5 mg nesiritide vial. Gently rock to dissolve. Do not shake. This gives 0.32 mg/mL.
Withdraw the full reconstituted volume and inject it back into the 250 mL IV bag. Final concentration is approximately 6 mcg/mL.
For a 70 kg patient, that is 140 mcg = 23.3 mL of the 6 mcg/mL solution. Administer over 60 seconds through a dedicated IV port.
Immediately start the continuous infusion at 0.01 mcg/kg/min. For 70 kg at 6 mcg/mL, set the pump to 7 mL/hr.
If response is inadequate, the rate may be increased up to 0.03 mcg/kg/min maximum. Do not uptitrate more often than every 3 hours. Each increase raises hypotension and renal risk.
If it drops below 90 mmHg, reduce or stop the infusion. Prepare IV fluid support if needed.
Do not co-administer through the same IV line with heparin, furosemide, bumetanide, ethacrynic acid, enalaprilat, insulin, or hydralazine. Physical incompatibility causes precipitation. Use a dedicated IV port.
Check serum creatinine and eGFR daily. Monitor urine output hourly. Track electrolytes every 24 hours.
After discontinuation, continue blood pressure monitoring for at least 2 hours. Hemodynamic effects outlast the 18-minute plasma half-life by a wide margin.
Physical incompatibility: precipitate forms in same IV line. Use dedicated port.
Do not combinePhysical incompatibility: do not co-administer via same IV line.
Do not combinePhysical incompatibility, not listed in original peptides.ts drug interactions but documented in FDA label.
Do not combinePhysical incompatibility, not listed in original peptides.ts drug interactions but documented in FDA label.
Do not combinePricing updated 2026-04-09
Hypotension is the primary concern with nesiritide, and it's worse than the 18-minute plasma half-life would suggest. Symptomatic blood pressure drops occur in about 4% of patients at the recommended dose, but the hemodynamic effects persist for roughly 2.2 hours on average after stopping the infusion. Compare that to nitroglycerin, where hypotension resolves in about 0.7 hours. You can't quickly reverse nesiritide's vasodilatory effects by turning off the drip. The 2005 Sackner-Bernstein meta-analysis [3] raised a more alarming flag: a 74% increase in 30-day mortality risk (p=0.059) across pooled trial data. ASCEND-HF did not confirm this signal (3.6% vs 4.0%, not statistically different), but the concern reshaped clinical practice permanently. Renal function deterioration is the second major issue. Patients with severe heart failure who depend on the renin-angiotensin-aldosterone system for renal perfusion are most vulnerable. Raised serum creatinine and declining eGFR were observed particularly at infusion rates above 0.01 mcg/kg/min. The 2005 renal meta-analysis [3] first documented this pattern. Ventricular tachycardia occurred in approximately 3% of patients in clinical trials. Headache is the most common non-cardiovascular side effect. Nausea, vomiting, dizziness, anxiety, insomnia, abdominal pain, and back pain have all been reported. Allergic reactions and anaphylaxis are rare but documented. The drug binds to receptors throughout the vasculature; hypersensitivity can produce systemic effects rapidly. If systolic blood pressure drops below 90 mmHg, the infusion should be reduced or stopped. Because the hemodynamic effects outlast the drug's presence in blood, IV fluid support may be needed while waiting for recovery. Continuous blood pressure monitoring is required during and for at least two hours after discontinuation. Any rise in serum creatinine during treatment warrants immediate dose reduction or cessation.
Verify Nesiritide (Natrecor) dosing and safety with a second opinion
Nesiritide is a discontinued FDA-regulated pharmaceutical (Natrecor). During availability, it was hospital-supply-chain only: no compounded or gray-market versions existed. Currently unavailable from any legitimate source; gray-market or counterfeit sourcing would be extremely high risk and unverifiable.
| Test | When | Target |
|---|---|---|
| Blood pressure (systolic) | Continuous during infusion; every 15 min for 1 hour post-bolus; every 30 min thereafter; 2+ hours post-discontinuation | Systolic ≥90 mmHg: reduce or stop infusion if BP falls below threshold |
| Serum creatinine / eGFR | Baseline before initiation; every 24 hours during infusion | No established target; watch for rising creatinine or falling eGFR trend |
| Pulmonary capillary wedge pressure (PCWP) | If pulmonary artery catheter in place: baseline, 1 hour, and as clinically indicated | Clinical reduction from elevated baseline (typically >18 mmHg at initiation) |
| Urine output / fluid balance | Hourly during infusion | >0.5 mL/kg/hr indicates adequate hemodynamic response |
| Serum electrolytes (Na, K) | Baseline and every 24 hours | — |
Primary dose-limiting toxicity; hypotension can be prolonged due to PD half-life exceeding PK half-life
Nesiritide can worsen renal function, particularly at doses >0.01 mcg/kg/min in RAAS-dependent patients
Primary hemodynamic endpoint; nesiritide approved for PCWP reduction in ADHF
Natriuretic effect is a primary mechanism; adequate urine output confirms efficacy
Natriuresis may cause electrolyte shifts; hypokalemia risk in combination with loop diuretics
Onset of hemodynamic effects with reduction in PCWP and right atrial pressure following IV bolus
Significant decrease in systemic vascular resistance, reduction in dyspnea symptoms, and improved cardiac output
Sustained hemodynamic improvement with peak vasodilatory and natriuretic effects during continuous infusion
Maintained hemodynamic stabilization; continued monitoring for hypotension and renal function required
Hemodynamic effects gradually resolve over approximately 60 minutes after discontinuation; systolic BP returns to baseline
0 to 15 minutes (Bolus onset): Hemodynamic effects begin almost immediately after the IV bolus. PCWP and right atrial pressure start falling within minutes. This is also the highest-risk window for acute hypotension, so blood pressure monitoring should already be running before the bolus goes in. 15 to 60 minutes (Early infusion): Systemic vascular resistance drops measurably. Cardiac output increases without direct inotropic stimulation. Some patients report modest dyspnea improvement in this window. Headache and dizziness may appear as blood pressure adjusts. 1 to 3 hours (Peak hemodynamic effect): Vasodilatory and natriuretic effects reach their maximum during continuous infusion. Urine output should be climbing if the drug is working. Symptomatic hypotension can persist or worsen even if the infusion rate hasn't changed; the pharmacodynamic curve keeps building beyond what the 18-minute plasma half-life would predict. 3 to 48 hours (Maintenance): Hemodynamic stabilization holds as long as the infusion runs. Renal function monitoring becomes the priority. Creatinine may start rising, particularly at rates above 0.01 mcg/kg/min. Ventricular tachycardia occurs in roughly 3% of patients during this window. Post-infusion (Recovery): After stopping the drip, blood pressure effects take about 2.2 hours to resolve on average. That's far longer than the 18-minute elimination half-life. Keep monitoring. IV fluids should be ready if systolic pressure stays below 90 mmHg. Dyspnea relief may outlast the hemodynamic effects.
Rapid reduction in PCWP and right atrial pressure following IV bolus; onset within minutes.
N/A: hospital-monitored setting only; no community data.
Significant decrease in SVR; modest improvement in dyspnea symptoms; increased cardiac output without direct inotropic stimulation.
N/A
Maximal vasodilatory and natriuretic effects during continuous infusion; urine output increases.
N/A
Sustained hemodynamic stabilization; renal function monitoring critical: creatinine rise possible at doses >0.01 mcg/kg/min.
N/A
Hemodynamic effects resolve over ~2.2 hours after discontinuation (PD half-life); systolic BP returns to baseline. Dyspnea relief may persist.
N/A
Source: FDA label: mean terminal elimination half-life ~18 minutes
Loading the interactive decay curve.
Nesiritide (Natrecor) received FDA approval in August 2001 for the intravenous treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. The NDA number is 020920. It was classified as a prescription drug for hospital use only, requiring administration by healthcare professionals with hemodynamic monitoring capability. The drug has been discontinued from the US market. Clinical use collapsed after the 2005 safety meta-analyses and the negative ASCEND-HF results in 2011. It is not available from any legitimate pharmaceutical supply chain for new clinical use. Any product marketed as nesiritide outside of a verified hospital pharmacy channel should be considered counterfeit and unsafe. Nesiritide is not a controlled substance. It has no WADA classification, as it has no performance-improving application. No compounding pharmacy equivalent exists. This content is for educational and clinical reference purposes only. It does not constitute medical advice.
Peptide Schedule Research TeamReviewed Apr 20264 Citations
